BioCentury
ARTICLE | Clinical News

Lenvatinib: Phase II data

October 8, 2012 7:00 AM UTC

Data from 32 patients with recurrent GBM who progressed on Avastin bevacizumab treatment in a single-arm Phase II trial showed that once-daily 24 mg lenvatinib produced no observed objective response...